MX342907B - El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. - Google Patents
El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.Info
- Publication number
- MX342907B MX342907B MX2011012048A MX2011012048A MX342907B MX 342907 B MX342907 B MX 342907B MX 2011012048 A MX2011012048 A MX 2011012048A MX 2011012048 A MX2011012048 A MX 2011012048A MX 342907 B MX342907 B MX 342907B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treating lupus
- patient
- lupus
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 206010025135 lupus erythematosus Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 230000000779 depleting effect Effects 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17792409P | 2009-05-13 | 2009-05-13 | |
| PCT/US2010/034741 WO2010132683A1 (en) | 2009-05-13 | 2010-05-13 | Methods and compositions for treating lupus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011012048A MX2011012048A (es) | 2011-12-12 |
| MX342907B true MX342907B (es) | 2016-10-17 |
Family
ID=43085330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012048A MX342907B (es) | 2009-05-13 | 2010-05-13 | El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9617343B2 (OSRAM) |
| EP (2) | EP2429583A4 (OSRAM) |
| JP (3) | JP5834004B2 (OSRAM) |
| KR (1) | KR101800467B1 (OSRAM) |
| CN (2) | CN102438654A (OSRAM) |
| AU (2) | AU2010248935B2 (OSRAM) |
| BR (1) | BRPI1013927A2 (OSRAM) |
| CA (1) | CA2761885A1 (OSRAM) |
| IL (1) | IL216146A0 (OSRAM) |
| MX (1) | MX342907B (OSRAM) |
| RU (1) | RU2607022C2 (OSRAM) |
| WO (1) | WO2010132683A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ621170A (en) | 2009-05-13 | 2015-08-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
| WO2013107413A1 (zh) * | 2012-01-19 | 2013-07-25 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
| JP6400604B2 (ja) * | 2013-02-08 | 2018-10-03 | アレゲーニー・シンガー リサーチ インスティチュート | プレループス診断用バイオマーカーとしての細胞結合性補体活性産物 |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| MX2015013364A (es) * | 2013-03-20 | 2015-12-15 | Hoffmann La Roche | Deteccion especifica de anticuerpos de rata en suero de raton. |
| EP3105317B1 (en) | 2014-02-14 | 2018-09-19 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CA2977106A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2020524512A (ja) | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| US7060802B1 (en) * | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20050191632A1 (en) * | 2002-11-01 | 2005-09-01 | John Byrd | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| WO2004087210A1 (ja) | 2003-03-31 | 2004-10-14 | Kirin Beer Kabushiki Kaisha | 抗cd52抗体による調節性t細胞分化誘導･増殖方法およびそのための医薬組成物 |
| CN1898267B (zh) | 2003-11-01 | 2012-05-23 | 默克专利股份有限公司 | 修饰的抗cd52抗体 |
| AU2005249360B2 (en) | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
| CN101443040A (zh) * | 2006-03-16 | 2009-05-27 | 基因技术股份有限公司 | 用cd4抗体治疗狼疮的方法 |
| EP2018156B1 (en) | 2006-04-07 | 2010-03-17 | Chimeros, Inc. | Compositions and methods for treating b- cell malignancies |
| CA2649440A1 (en) * | 2006-04-12 | 2007-10-25 | Genzyme Corporation | Methods of treating autoimmune diseases |
| GB0608054D0 (en) | 2006-04-24 | 2006-05-31 | Isis Innovation | Production and use of regulatory t cells |
| EP2029729A2 (en) * | 2006-05-31 | 2009-03-04 | Genzyme Corporation | Methods of using anti-thymocyte globulin and related agents |
| US9683026B2 (en) | 2006-07-19 | 2017-06-20 | The Trustees Of The University Of Pennslyvania | WSX-1/P28 as a target for anti-inflammatory responses |
| US8148067B2 (en) | 2006-11-09 | 2012-04-03 | Xdx, Inc. | Methods for diagnosing and monitoring the status of systemic lupus erythematosus |
| NZ621170A (en) | 2009-05-13 | 2015-08-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
-
2010
- 2010-05-13 CN CN2010800209534A patent/CN102438654A/zh active Pending
- 2010-05-13 WO PCT/US2010/034741 patent/WO2010132683A1/en not_active Ceased
- 2010-05-13 EP EP10775545.6A patent/EP2429583A4/en not_active Withdrawn
- 2010-05-13 EP EP17206028.7A patent/EP3345620B1/en active Active
- 2010-05-13 JP JP2012511015A patent/JP5834004B2/ja active Active
- 2010-05-13 KR KR1020117029688A patent/KR101800467B1/ko active Active
- 2010-05-13 CN CN201910644240.8A patent/CN110179989B/zh active Active
- 2010-05-13 US US13/320,001 patent/US9617343B2/en active Active
- 2010-05-13 BR BRPI1013927A patent/BRPI1013927A2/pt not_active Application Discontinuation
- 2010-05-13 RU RU2011150495A patent/RU2607022C2/ru active
- 2010-05-13 CA CA2761885A patent/CA2761885A1/en not_active Withdrawn
- 2010-05-13 AU AU2010248935A patent/AU2010248935B2/en active Active
- 2010-05-13 MX MX2011012048A patent/MX342907B/es active IP Right Grant
-
2011
- 2011-11-03 IL IL216146A patent/IL216146A0/en active IP Right Grant
-
2014
- 2014-12-11 JP JP2014250861A patent/JP2015052021A/ja not_active Withdrawn
-
2016
- 2016-10-06 JP JP2016197833A patent/JP2017008106A/ja active Pending
-
2017
- 2017-03-01 US US15/446,162 patent/US20170369583A1/en not_active Abandoned
- 2017-03-15 AU AU2017201771A patent/AU2017201771A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2429583A4 (en) | 2013-10-16 |
| BRPI1013927A2 (pt) | 2016-04-05 |
| US9617343B2 (en) | 2017-04-11 |
| KR20140014392A (ko) | 2014-02-06 |
| IL216146A0 (en) | 2012-01-31 |
| EP2429583A1 (en) | 2012-03-21 |
| US20170369583A1 (en) | 2017-12-28 |
| RU2607022C2 (ru) | 2017-01-10 |
| AU2010248935B2 (en) | 2016-12-15 |
| AU2017201771A1 (en) | 2017-04-06 |
| EP3345620B1 (en) | 2024-08-28 |
| JP2015052021A (ja) | 2015-03-19 |
| CN110179989B (zh) | 2022-06-24 |
| WO2010132683A1 (en) | 2010-11-18 |
| CA2761885A1 (en) | 2010-11-18 |
| CN110179989A (zh) | 2019-08-30 |
| CN102438654A (zh) | 2012-05-02 |
| KR101800467B1 (ko) | 2017-11-22 |
| MX2011012048A (es) | 2011-12-12 |
| JP5834004B2 (ja) | 2015-12-16 |
| EP3345620A1 (en) | 2018-07-11 |
| AU2010248935A1 (en) | 2011-11-17 |
| JP2012526846A (ja) | 2012-11-01 |
| RU2011150495A (ru) | 2013-06-20 |
| US20120070408A1 (en) | 2012-03-22 |
| JP2017008106A (ja) | 2017-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011012048A (es) | Metodos y composiciones para el tratamiento del lupus. | |
| GB2471588A (en) | Therapeutic peptidomimetic macrocycles | |
| JO2828B1 (en) | Anti-Hepsidine antibodies and their uses | |
| MY160041A (en) | Compositions and methods for treating parasitic infections | |
| MX2009005849A (es) | Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas. | |
| PH12015500093A1 (en) | Il-17 binding proteins | |
| SG166093A1 (en) | Inhibitors of brutonæs tyrosine kinase | |
| ATE540709T1 (de) | Implantierbare medizinische vorrichtung mit partikelbeschichtung | |
| MA33256B1 (fr) | Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation | |
| UA101944C2 (ru) | Композиции и способы применения для антител dickopf-1 | |
| SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| PH12017501075B1 (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof | |
| EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
| WO2008034076A3 (en) | Cyclophosphamide in combination with immune therapeutics | |
| EP2614085A4 (en) | ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE | |
| WO2008112003A3 (en) | Targeted binding agents directed to pdgfr-alpha and uses thereof | |
| MA34722B1 (fr) | Méthodes et compositions pour l'immunothérapie de maladies neurales | |
| WO2009023333A3 (en) | Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines | |
| WO2009017655A3 (en) | Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof | |
| MY173304A (en) | Induction of immune tolerance using methotrexate | |
| WO2008085962A3 (en) | Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants | |
| PH12013502194A1 (en) | Antibodies to egfl7 and methods for their use | |
| WO2006002377A3 (en) | Optimized dosing with anti-cd4 antibodies for tolerance induction in primates | |
| GR20120100415A (el) | Μεθοδος αμεσης ανιχνευσης του μυκοβακτηριδιου της φυματιωσης | |
| WO2011130249A3 (en) | Methods and compositions for inhibition of treg cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |